DV
Dividend Vision

TECX — Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. (TECX)

Total return is -90.7% over the past 8.1 years, 310.4 points behind SPY at 219.7%. Its deepest 1-year drawdown was 44.6%.

Tectonic Therapeutic is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein coupled receptors (GPCRs), using its proprietary GEODe technology platform. The company's pipeline includes TX45, a Fc-relaxin fusion molecule in development for RXFP1 receptor activation, along with TX2100 for hereditary hemorrhagic telangiectasia and other GPCR-targeted biologic medicines. The company does not currently distribute dividends, making it oriented toward investors seeking exposure to clinical-stage biotech development rather than current income.

TECX key facts

Asset type
Stock
Asset class
Equity
Inception date
06/21/2018
Last close
$34.91
Market cap
$605,134,784
Average volume
84200.0
Beta
0.098
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.39